nodes	percent_of_prediction	percent_of_DWPC	metapath
Deferiprone—Hepatobiliary disease—Vandetanib—thyroid cancer	0.00674	0.00674	CcSEcCtD
Deferiprone—Epistaxis—Vandetanib—thyroid cancer	0.00672	0.00672	CcSEcCtD
Deferiprone—Furuncle—Epirubicin—thyroid cancer	0.00648	0.00648	CcSEcCtD
Deferiprone—Myositis—Epirubicin—thyroid cancer	0.00648	0.00648	CcSEcCtD
Deferiprone—Cardiac failure—Sorafenib—thyroid cancer	0.00639	0.00639	CcSEcCtD
Deferiprone—Muscle relaxant therapy—Epirubicin—thyroid cancer	0.00638	0.00638	CcSEcCtD
Deferiprone—Urinary tract disorder—Vandetanib—thyroid cancer	0.00632	0.00632	CcSEcCtD
Deferiprone—Urethral disorder—Vandetanib—thyroid cancer	0.00627	0.00627	CcSEcCtD
Deferiprone—Pain in extremity—Sorafenib—thyroid cancer	0.00624	0.00624	CcSEcCtD
Deferiprone—Hypotonia—Epirubicin—thyroid cancer	0.00604	0.00604	CcSEcCtD
Deferiprone—Furuncle—Doxorubicin—thyroid cancer	0.00599	0.00599	CcSEcCtD
Deferiprone—Myositis—Doxorubicin—thyroid cancer	0.00599	0.00599	CcSEcCtD
Deferiprone—Eye disorder—Vandetanib—thyroid cancer	0.00598	0.00598	CcSEcCtD
Deferiprone—Cardiac disorder—Vandetanib—thyroid cancer	0.00594	0.00594	CcSEcCtD
Deferiprone—Muscle relaxant therapy—Doxorubicin—thyroid cancer	0.00591	0.00591	CcSEcCtD
Deferiprone—Angiopathy—Vandetanib—thyroid cancer	0.0058	0.0058	CcSEcCtD
Deferiprone—Dehydration—Sorafenib—thyroid cancer	0.0058	0.0058	CcSEcCtD
Deferiprone—Mediastinal disorder—Vandetanib—thyroid cancer	0.00577	0.00577	CcSEcCtD
Deferiprone—Aspartate aminotransferase increased—Sorafenib—thyroid cancer	0.00562	0.00562	CcSEcCtD
Deferiprone—Mental disorder—Vandetanib—thyroid cancer	0.0056	0.0056	CcSEcCtD
Deferiprone—Hypotonia—Doxorubicin—thyroid cancer	0.00559	0.00559	CcSEcCtD
Deferiprone—Malnutrition—Vandetanib—thyroid cancer	0.00557	0.00557	CcSEcCtD
Deferiprone—Alanine aminotransferase increased—Sorafenib—thyroid cancer	0.0055	0.0055	CcSEcCtD
Deferiprone—Gastric ulcer—Epirubicin—thyroid cancer	0.00546	0.00546	CcSEcCtD
Deferiprone—Pancreatitis—Sorafenib—thyroid cancer	0.00529	0.00529	CcSEcCtD
Deferiprone—Optic neuritis—Epirubicin—thyroid cancer	0.00516	0.00516	CcSEcCtD
Deferiprone—Thrombocytosis—Epirubicin—thyroid cancer	0.00511	0.00511	CcSEcCtD
Deferiprone—Gastric ulcer—Doxorubicin—thyroid cancer	0.00506	0.00506	CcSEcCtD
Deferiprone—Neutropenia—Sorafenib—thyroid cancer	0.00504	0.00504	CcSEcCtD
Deferiprone—Pneumonia—Sorafenib—thyroid cancer	0.00484	0.00484	CcSEcCtD
Deferiprone—Convulsion—Vandetanib—thyroid cancer	0.00483	0.00483	CcSEcCtD
Deferiprone—Hypertension—Vandetanib—thyroid cancer	0.00481	0.00481	CcSEcCtD
Deferiprone—Infestation NOS—Sorafenib—thyroid cancer	0.00481	0.00481	CcSEcCtD
Deferiprone—Infestation—Sorafenib—thyroid cancer	0.00481	0.00481	CcSEcCtD
Deferiprone—Optic neuritis—Doxorubicin—thyroid cancer	0.00478	0.00478	CcSEcCtD
Deferiprone—Arthralgia—Vandetanib—thyroid cancer	0.00474	0.00474	CcSEcCtD
Deferiprone—Thrombocytosis—Doxorubicin—thyroid cancer	0.00473	0.00473	CcSEcCtD
Deferiprone—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.00471	0.00471	CcSEcCtD
Deferiprone—Jaundice—Sorafenib—thyroid cancer	0.00469	0.00469	CcSEcCtD
Deferiprone—Hepatobiliary disease—Sorafenib—thyroid cancer	0.00455	0.00455	CcSEcCtD
Deferiprone—Epistaxis—Sorafenib—thyroid cancer	0.00453	0.00453	CcSEcCtD
Deferiprone—Infection—Vandetanib—thyroid cancer	0.00452	0.00452	CcSEcCtD
Deferiprone—Hepatomegaly—Epirubicin—thyroid cancer	0.00449	0.00449	CcSEcCtD
Deferiprone—Nervous system disorder—Vandetanib—thyroid cancer	0.00446	0.00446	CcSEcCtD
Deferiprone—Nystagmus—Epirubicin—thyroid cancer	0.00445	0.00445	CcSEcCtD
Deferiprone—Skin disorder—Vandetanib—thyroid cancer	0.00441	0.00441	CcSEcCtD
Deferiprone—Haemoptysis—Epirubicin—thyroid cancer	0.00429	0.00429	CcSEcCtD
Deferiprone—Urinary tract disorder—Sorafenib—thyroid cancer	0.00426	0.00426	CcSEcCtD
Deferiprone—Connective tissue disorder—Sorafenib—thyroid cancer	0.00424	0.00424	CcSEcCtD
Deferiprone—Urethral disorder—Sorafenib—thyroid cancer	0.00423	0.00423	CcSEcCtD
Deferiprone—Hepatomegaly—Doxorubicin—thyroid cancer	0.00415	0.00415	CcSEcCtD
Deferiprone—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.00414	0.00414	CcSEcCtD
Deferiprone—Nystagmus—Doxorubicin—thyroid cancer	0.00411	0.00411	CcSEcCtD
Deferiprone—Cardiac disorder—Sorafenib—thyroid cancer	0.00401	0.00401	CcSEcCtD
Deferiprone—Dyspepsia—Vandetanib—thyroid cancer	0.004	0.004	CcSEcCtD
Deferiprone—Rash pustular—Epirubicin—thyroid cancer	0.00398	0.00398	CcSEcCtD
Deferiprone—Haemoptysis—Doxorubicin—thyroid cancer	0.00397	0.00397	CcSEcCtD
Deferiprone—Decreased appetite—Vandetanib—thyroid cancer	0.00395	0.00395	CcSEcCtD
Deferiprone—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00392	0.00392	CcSEcCtD
Deferiprone—Glycosuria—Epirubicin—thyroid cancer	0.00392	0.00392	CcSEcCtD
Deferiprone—Fatigue—Vandetanib—thyroid cancer	0.00392	0.00392	CcSEcCtD
Deferiprone—Angiopathy—Sorafenib—thyroid cancer	0.00392	0.00392	CcSEcCtD
Deferiprone—Immune system disorder—Sorafenib—thyroid cancer	0.0039	0.0039	CcSEcCtD
Deferiprone—Mediastinal disorder—Sorafenib—thyroid cancer	0.00389	0.00389	CcSEcCtD
Deferiprone—Pain—Vandetanib—thyroid cancer	0.00389	0.00389	CcSEcCtD
Deferiprone—Mental disorder—Sorafenib—thyroid cancer	0.00378	0.00378	CcSEcCtD
Deferiprone—Malnutrition—Sorafenib—thyroid cancer	0.00376	0.00376	CcSEcCtD
Deferiprone—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00372	0.00372	CcSEcCtD
Deferiprone—Rash pustular—Doxorubicin—thyroid cancer	0.00368	0.00368	CcSEcCtD
Deferiprone—Glycosuria—Doxorubicin—thyroid cancer	0.00363	0.00363	CcSEcCtD
Deferiprone—Body temperature increased—Vandetanib—thyroid cancer	0.00359	0.00359	CcSEcCtD
Deferiprone—Abdominal pain—Vandetanib—thyroid cancer	0.00359	0.00359	CcSEcCtD
Deferiprone—Rectal haemorrhage—Epirubicin—thyroid cancer	0.00352	0.00352	CcSEcCtD
Deferiprone—Arthropathy—Epirubicin—thyroid cancer	0.00349	0.00349	CcSEcCtD
Deferiprone—Blood bilirubin increased—Epirubicin—thyroid cancer	0.00336	0.00336	CcSEcCtD
Deferiprone—Asthenia—Vandetanib—thyroid cancer	0.00326	0.00326	CcSEcCtD
Deferiprone—Gait disturbance—Epirubicin—thyroid cancer	0.00325	0.00325	CcSEcCtD
Deferiprone—Rectal haemorrhage—Doxorubicin—thyroid cancer	0.00325	0.00325	CcSEcCtD
Deferiprone—Hypertension—Sorafenib—thyroid cancer	0.00324	0.00324	CcSEcCtD
Deferiprone—Arthropathy—Doxorubicin—thyroid cancer	0.00323	0.00323	CcSEcCtD
Deferiprone—Pruritus—Vandetanib—thyroid cancer	0.00322	0.00322	CcSEcCtD
Deferiprone—Arthralgia—Sorafenib—thyroid cancer	0.0032	0.0032	CcSEcCtD
Deferiprone—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00318	0.00318	CcSEcCtD
Deferiprone—Pulmonary embolism—Epirubicin—thyroid cancer	0.00318	0.00318	CcSEcCtD
Deferiprone—Diarrhoea—Vandetanib—thyroid cancer	0.00311	0.00311	CcSEcCtD
Deferiprone—Blood bilirubin increased—Doxorubicin—thyroid cancer	0.00311	0.00311	CcSEcCtD
Deferiprone—Anaphylactic shock—Sorafenib—thyroid cancer	0.00307	0.00307	CcSEcCtD
Deferiprone—Infection—Sorafenib—thyroid cancer	0.00305	0.00305	CcSEcCtD
Deferiprone—Gait disturbance—Doxorubicin—thyroid cancer	0.00301	0.00301	CcSEcCtD
Deferiprone—Nervous system disorder—Sorafenib—thyroid cancer	0.00301	0.00301	CcSEcCtD
Deferiprone—Skin disorder—Sorafenib—thyroid cancer	0.00298	0.00298	CcSEcCtD
Deferiprone—Pulmonary embolism—Doxorubicin—thyroid cancer	0.00294	0.00294	CcSEcCtD
Deferiprone—Vomiting—Vandetanib—thyroid cancer	0.00289	0.00289	CcSEcCtD
Deferiprone—Rash—Vandetanib—thyroid cancer	0.00287	0.00287	CcSEcCtD
Deferiprone—Dermatitis—Vandetanib—thyroid cancer	0.00286	0.00286	CcSEcCtD
Deferiprone—Headache—Vandetanib—thyroid cancer	0.00285	0.00285	CcSEcCtD
Deferiprone—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.00279	0.00279	CcSEcCtD
Deferiprone—Sepsis—Epirubicin—thyroid cancer	0.00276	0.00276	CcSEcCtD
Deferiprone—Nausea—Vandetanib—thyroid cancer	0.0027	0.0027	CcSEcCtD
Deferiprone—Dyspepsia—Sorafenib—thyroid cancer	0.0027	0.0027	CcSEcCtD
Deferiprone—Decreased appetite—Sorafenib—thyroid cancer	0.00267	0.00267	CcSEcCtD
Deferiprone—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00265	0.00265	CcSEcCtD
Deferiprone—Fatigue—Sorafenib—thyroid cancer	0.00264	0.00264	CcSEcCtD
Deferiprone—Pain—Sorafenib—thyroid cancer	0.00262	0.00262	CcSEcCtD
Deferiprone—Sepsis—Doxorubicin—thyroid cancer	0.00255	0.00255	CcSEcCtD
Deferiprone—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00251	0.00251	CcSEcCtD
Deferiprone—Increased appetite—Epirubicin—thyroid cancer	0.00245	0.00245	CcSEcCtD
Deferiprone—Urticaria—Sorafenib—thyroid cancer	0.00244	0.00244	CcSEcCtD
Deferiprone—Abdominal pain—Sorafenib—thyroid cancer	0.00242	0.00242	CcSEcCtD
Deferiprone—Body temperature increased—Sorafenib—thyroid cancer	0.00242	0.00242	CcSEcCtD
Deferiprone—Cardiac failure—Epirubicin—thyroid cancer	0.00236	0.00236	CcSEcCtD
Deferiprone—Pain in extremity—Epirubicin—thyroid cancer	0.00231	0.00231	CcSEcCtD
Deferiprone—Diplopia—Epirubicin—thyroid cancer	0.00231	0.00231	CcSEcCtD
Deferiprone—Osteoarthritis—Epirubicin—thyroid cancer	0.00231	0.00231	CcSEcCtD
Deferiprone—Increased appetite—Doxorubicin—thyroid cancer	0.00227	0.00227	CcSEcCtD
Deferiprone—Hypersensitivity—Sorafenib—thyroid cancer	0.00226	0.00226	CcSEcCtD
Deferiprone—Asthenia—Sorafenib—thyroid cancer	0.0022	0.0022	CcSEcCtD
Deferiprone—Cardiac failure—Doxorubicin—thyroid cancer	0.00219	0.00219	CcSEcCtD
Deferiprone—Pruritus—Sorafenib—thyroid cancer	0.00217	0.00217	CcSEcCtD
Deferiprone—Dehydration—Epirubicin—thyroid cancer	0.00214	0.00214	CcSEcCtD
Deferiprone—Diplopia—Doxorubicin—thyroid cancer	0.00213	0.00213	CcSEcCtD
Deferiprone—Osteoarthritis—Doxorubicin—thyroid cancer	0.00213	0.00213	CcSEcCtD
Deferiprone—Pain in extremity—Doxorubicin—thyroid cancer	0.00213	0.00213	CcSEcCtD
Deferiprone—Diarrhoea—Sorafenib—thyroid cancer	0.0021	0.0021	CcSEcCtD
Deferiprone—Aspartate aminotransferase increased—Epirubicin—thyroid cancer	0.00208	0.00208	CcSEcCtD
Deferiprone—Alanine aminotransferase increased—Epirubicin—thyroid cancer	0.00203	0.00203	CcSEcCtD
Deferiprone—Dehydration—Doxorubicin—thyroid cancer	0.00198	0.00198	CcSEcCtD
Deferiprone—Pancreatitis—Epirubicin—thyroid cancer	0.00195	0.00195	CcSEcCtD
Deferiprone—Vomiting—Sorafenib—thyroid cancer	0.00195	0.00195	CcSEcCtD
Deferiprone—Rash—Sorafenib—thyroid cancer	0.00193	0.00193	CcSEcCtD
Deferiprone—Dermatitis—Sorafenib—thyroid cancer	0.00193	0.00193	CcSEcCtD
Deferiprone—Aspartate aminotransferase increased—Doxorubicin—thyroid cancer	0.00192	0.00192	CcSEcCtD
Deferiprone—Headache—Sorafenib—thyroid cancer	0.00192	0.00192	CcSEcCtD
Deferiprone—Pancytopenia—Epirubicin—thyroid cancer	0.00189	0.00189	CcSEcCtD
Deferiprone—Alanine aminotransferase increased—Doxorubicin—thyroid cancer	0.00188	0.00188	CcSEcCtD
Deferiprone—Neutropenia—Epirubicin—thyroid cancer	0.00186	0.00186	CcSEcCtD
Deferiprone—Nausea—Sorafenib—thyroid cancer	0.00182	0.00182	CcSEcCtD
Deferiprone—Photosensitivity reaction—Epirubicin—thyroid cancer	0.00182	0.00182	CcSEcCtD
Deferiprone—Weight increased—Epirubicin—thyroid cancer	0.00181	0.00181	CcSEcCtD
Deferiprone—Pancreatitis—Doxorubicin—thyroid cancer	0.00181	0.00181	CcSEcCtD
Deferiprone—Pneumonia—Epirubicin—thyroid cancer	0.00179	0.00179	CcSEcCtD
Deferiprone—Infestation—Epirubicin—thyroid cancer	0.00178	0.00178	CcSEcCtD
Deferiprone—Infestation NOS—Epirubicin—thyroid cancer	0.00178	0.00178	CcSEcCtD
Deferiprone—Pancytopenia—Doxorubicin—thyroid cancer	0.00175	0.00175	CcSEcCtD
Deferiprone—Jaundice—Epirubicin—thyroid cancer	0.00173	0.00173	CcSEcCtD
Deferiprone—Neutropenia—Doxorubicin—thyroid cancer	0.00172	0.00172	CcSEcCtD
Deferiprone—Photosensitivity reaction—Doxorubicin—thyroid cancer	0.00168	0.00168	CcSEcCtD
Deferiprone—Hepatobiliary disease—Epirubicin—thyroid cancer	0.00168	0.00168	CcSEcCtD
Deferiprone—Weight increased—Doxorubicin—thyroid cancer	0.00168	0.00168	CcSEcCtD
Deferiprone—Epistaxis—Epirubicin—thyroid cancer	0.00168	0.00168	CcSEcCtD
Deferiprone—Agranulocytosis—Epirubicin—thyroid cancer	0.00166	0.00166	CcSEcCtD
Deferiprone—Pneumonia—Doxorubicin—thyroid cancer	0.00165	0.00165	CcSEcCtD
Deferiprone—Infestation—Doxorubicin—thyroid cancer	0.00164	0.00164	CcSEcCtD
Deferiprone—Infestation NOS—Doxorubicin—thyroid cancer	0.00164	0.00164	CcSEcCtD
Deferiprone—Jaundice—Doxorubicin—thyroid cancer	0.0016	0.0016	CcSEcCtD
Deferiprone—Hepatitis—Epirubicin—thyroid cancer	0.00159	0.00159	CcSEcCtD
Deferiprone—Pharyngitis—Epirubicin—thyroid cancer	0.00158	0.00158	CcSEcCtD
Deferiprone—Urinary tract disorder—Epirubicin—thyroid cancer	0.00158	0.00158	CcSEcCtD
Deferiprone—Oedema peripheral—Epirubicin—thyroid cancer	0.00157	0.00157	CcSEcCtD
Deferiprone—Connective tissue disorder—Epirubicin—thyroid cancer	0.00157	0.00157	CcSEcCtD
Deferiprone—Urethral disorder—Epirubicin—thyroid cancer	0.00156	0.00156	CcSEcCtD
Deferiprone—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.00155	0.00155	CcSEcCtD
Deferiprone—Epistaxis—Doxorubicin—thyroid cancer	0.00155	0.00155	CcSEcCtD
Deferiprone—Agranulocytosis—Doxorubicin—thyroid cancer	0.00153	0.00153	CcSEcCtD
Deferiprone—Eye disorder—Epirubicin—thyroid cancer	0.00149	0.00149	CcSEcCtD
Deferiprone—Cardiac disorder—Epirubicin—thyroid cancer	0.00148	0.00148	CcSEcCtD
Deferiprone—Hepatitis—Doxorubicin—thyroid cancer	0.00148	0.00148	CcSEcCtD
Deferiprone—Pharyngitis—Doxorubicin—thyroid cancer	0.00146	0.00146	CcSEcCtD
Deferiprone—Urinary tract disorder—Doxorubicin—thyroid cancer	0.00146	0.00146	CcSEcCtD
Deferiprone—Oedema peripheral—Doxorubicin—thyroid cancer	0.00145	0.00145	CcSEcCtD
Deferiprone—Connective tissue disorder—Doxorubicin—thyroid cancer	0.00145	0.00145	CcSEcCtD
Deferiprone—Angiopathy—Epirubicin—thyroid cancer	0.00145	0.00145	CcSEcCtD
Deferiprone—Urethral disorder—Doxorubicin—thyroid cancer	0.00145	0.00145	CcSEcCtD
Deferiprone—Immune system disorder—Epirubicin—thyroid cancer	0.00144	0.00144	CcSEcCtD
Deferiprone—Mediastinal disorder—Epirubicin—thyroid cancer	0.00144	0.00144	CcSEcCtD
Deferiprone—Chills—Epirubicin—thyroid cancer	0.00143	0.00143	CcSEcCtD
Deferiprone—Mental disorder—Epirubicin—thyroid cancer	0.0014	0.0014	CcSEcCtD
Deferiprone—Malnutrition—Epirubicin—thyroid cancer	0.00139	0.00139	CcSEcCtD
Deferiprone—Eye disorder—Doxorubicin—thyroid cancer	0.00138	0.00138	CcSEcCtD
Deferiprone—Cardiac disorder—Doxorubicin—thyroid cancer	0.00137	0.00137	CcSEcCtD
Deferiprone—Back pain—Epirubicin—thyroid cancer	0.00134	0.00134	CcSEcCtD
Deferiprone—Angiopathy—Doxorubicin—thyroid cancer	0.00134	0.00134	CcSEcCtD
Deferiprone—Immune system disorder—Doxorubicin—thyroid cancer	0.00133	0.00133	CcSEcCtD
Deferiprone—Mediastinal disorder—Doxorubicin—thyroid cancer	0.00133	0.00133	CcSEcCtD
Deferiprone—Chills—Doxorubicin—thyroid cancer	0.00132	0.00132	CcSEcCtD
Deferiprone—Mental disorder—Doxorubicin—thyroid cancer	0.00129	0.00129	CcSEcCtD
Deferiprone—Malnutrition—Doxorubicin—thyroid cancer	0.00128	0.00128	CcSEcCtD
Deferiprone—Back pain—Doxorubicin—thyroid cancer	0.00124	0.00124	CcSEcCtD
Deferiprone—Convulsion—Epirubicin—thyroid cancer	0.0012	0.0012	CcSEcCtD
Deferiprone—Hypertension—Epirubicin—thyroid cancer	0.0012	0.0012	CcSEcCtD
Deferiprone—Arthralgia—Epirubicin—thyroid cancer	0.00118	0.00118	CcSEcCtD
Deferiprone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.00117	0.00117	CcSEcCtD
Deferiprone—Discomfort—Epirubicin—thyroid cancer	0.00117	0.00117	CcSEcCtD
Deferiprone—Anaphylactic shock—Epirubicin—thyroid cancer	0.00113	0.00113	CcSEcCtD
Deferiprone—Infection—Epirubicin—thyroid cancer	0.00113	0.00113	CcSEcCtD
Deferiprone—Convulsion—Doxorubicin—thyroid cancer	0.00111	0.00111	CcSEcCtD
Deferiprone—Nervous system disorder—Epirubicin—thyroid cancer	0.00111	0.00111	CcSEcCtD
Deferiprone—Hypertension—Doxorubicin—thyroid cancer	0.00111	0.00111	CcSEcCtD
Deferiprone—Skin disorder—Epirubicin—thyroid cancer	0.0011	0.0011	CcSEcCtD
Deferiprone—Hyperhidrosis—Epirubicin—thyroid cancer	0.0011	0.0011	CcSEcCtD
Deferiprone—Arthralgia—Doxorubicin—thyroid cancer	0.00109	0.00109	CcSEcCtD
Deferiprone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.00109	0.00109	CcSEcCtD
Deferiprone—Discomfort—Doxorubicin—thyroid cancer	0.00108	0.00108	CcSEcCtD
Deferiprone—Hypotension—Epirubicin—thyroid cancer	0.00106	0.00106	CcSEcCtD
Deferiprone—Anaphylactic shock—Doxorubicin—thyroid cancer	0.00105	0.00105	CcSEcCtD
Deferiprone—Infection—Doxorubicin—thyroid cancer	0.00104	0.00104	CcSEcCtD
Deferiprone—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.00103	0.00103	CcSEcCtD
Deferiprone—Nervous system disorder—Doxorubicin—thyroid cancer	0.00103	0.00103	CcSEcCtD
Deferiprone—Skin disorder—Doxorubicin—thyroid cancer	0.00102	0.00102	CcSEcCtD
Deferiprone—Hyperhidrosis—Doxorubicin—thyroid cancer	0.00101	0.00101	CcSEcCtD
Deferiprone—Somnolence—Epirubicin—thyroid cancer	0.00101	0.00101	CcSEcCtD
Deferiprone—Dyspepsia—Epirubicin—thyroid cancer	0.000997	0.000997	CcSEcCtD
Deferiprone—Decreased appetite—Epirubicin—thyroid cancer	0.000985	0.000985	CcSEcCtD
Deferiprone—Hypotension—Doxorubicin—thyroid cancer	0.00098	0.00098	CcSEcCtD
Deferiprone—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000978	0.000978	CcSEcCtD
Deferiprone—Fatigue—Epirubicin—thyroid cancer	0.000977	0.000977	CcSEcCtD
Deferiprone—Pain—Epirubicin—thyroid cancer	0.000969	0.000969	CcSEcCtD
Deferiprone—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000955	0.000955	CcSEcCtD
Deferiprone—Somnolence—Doxorubicin—thyroid cancer	0.000932	0.000932	CcSEcCtD
Deferiprone—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000927	0.000927	CcSEcCtD
Deferiprone—Dyspepsia—Doxorubicin—thyroid cancer	0.000923	0.000923	CcSEcCtD
Deferiprone—Decreased appetite—Doxorubicin—thyroid cancer	0.000911	0.000911	CcSEcCtD
Deferiprone—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000905	0.000905	CcSEcCtD
Deferiprone—Fatigue—Doxorubicin—thyroid cancer	0.000904	0.000904	CcSEcCtD
Deferiprone—Urticaria—Epirubicin—thyroid cancer	0.0009	0.0009	CcSEcCtD
Deferiprone—Pain—Doxorubicin—thyroid cancer	0.000897	0.000897	CcSEcCtD
Deferiprone—Abdominal pain—Epirubicin—thyroid cancer	0.000896	0.000896	CcSEcCtD
Deferiprone—Body temperature increased—Epirubicin—thyroid cancer	0.000896	0.000896	CcSEcCtD
Deferiprone—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000857	0.000857	CcSEcCtD
Deferiprone—Hypersensitivity—Epirubicin—thyroid cancer	0.000835	0.000835	CcSEcCtD
Deferiprone—Urticaria—Doxorubicin—thyroid cancer	0.000833	0.000833	CcSEcCtD
Deferiprone—Body temperature increased—Doxorubicin—thyroid cancer	0.000829	0.000829	CcSEcCtD
Deferiprone—Abdominal pain—Doxorubicin—thyroid cancer	0.000829	0.000829	CcSEcCtD
Deferiprone—Asthenia—Epirubicin—thyroid cancer	0.000813	0.000813	CcSEcCtD
Deferiprone—Pruritus—Epirubicin—thyroid cancer	0.000802	0.000802	CcSEcCtD
Deferiprone—Diarrhoea—Epirubicin—thyroid cancer	0.000775	0.000775	CcSEcCtD
Deferiprone—Hypersensitivity—Doxorubicin—thyroid cancer	0.000772	0.000772	CcSEcCtD
Deferiprone—Asthenia—Doxorubicin—thyroid cancer	0.000752	0.000752	CcSEcCtD
Deferiprone—Pruritus—Doxorubicin—thyroid cancer	0.000742	0.000742	CcSEcCtD
Deferiprone—Vomiting—Epirubicin—thyroid cancer	0.00072	0.00072	CcSEcCtD
Deferiprone—Diarrhoea—Doxorubicin—thyroid cancer	0.000717	0.000717	CcSEcCtD
Deferiprone—Rash—Epirubicin—thyroid cancer	0.000714	0.000714	CcSEcCtD
Deferiprone—Dermatitis—Epirubicin—thyroid cancer	0.000714	0.000714	CcSEcCtD
Deferiprone—Headache—Epirubicin—thyroid cancer	0.00071	0.00071	CcSEcCtD
Deferiprone—Nausea—Epirubicin—thyroid cancer	0.000673	0.000673	CcSEcCtD
Deferiprone—Vomiting—Doxorubicin—thyroid cancer	0.000667	0.000667	CcSEcCtD
Deferiprone—Rash—Doxorubicin—thyroid cancer	0.000661	0.000661	CcSEcCtD
Deferiprone—Dermatitis—Doxorubicin—thyroid cancer	0.00066	0.00066	CcSEcCtD
Deferiprone—Headache—Doxorubicin—thyroid cancer	0.000657	0.000657	CcSEcCtD
Deferiprone—Nausea—Doxorubicin—thyroid cancer	0.000623	0.000623	CcSEcCtD
